China's universities are wooing Western scientists
A handful of senior Western scholars have recently taken up posts in China, at universities such as Tsinghua. PHOTO: TSINGHUA.EDU.CN
Dr Charles Lieber had few options. On April 28, the renowned former Harvard chemist took up a new post at Tsinghua University's Shenzhen campus. Dr Lieber had been looking for a perch after he was convicted in America in 2021 for hiding ties to Chinese research funding. He is one of a handful of senior Western scholars who have recently taken up posts in China. Others have done so more from a position of choice.
The websites of Peking University and Tsinghua University, respectively, recently confirmed that Dr Gerard Mourou, a French Nobel prize-winning physicist, and Dr Kenji Fukaya, a decorated Japanese mathematician, were joining their faculties.
Join ST's Telegram channel and get the latest breaking news delivered to you.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
7 hours ago
- Business Times
Why China biotech is getting a DeepSeek moment, too
FROM artificial intelligence to military defence, China has offered a few DeepSeek moments this year, showing that the country is more than just the world's biggest factory, and that it also can compete with the United States on the technology front. Now biotech is having its own. In late May, Pfizer agreed to pay a record US$1.25 billion upfront to license an experimental cancer drug from Shenyang-based 3SBio, as well as making a US$100 million equity investment in the Hong Kong-listed biotech company. Two weeks later, Bristol-Myers Squibb said it would pay BioNTech US$1.5 billion guaranteed to license a similar cancer asset. It was a win for BioNTech, which bought Biotheus, the Chinese company that developed the drug, late last year for US$800 million. Increasingly, big pharmaceutical companies are seeing Chinese biotech as the disruptors. These two deals will allow Pfizer and Bristol-Myers Squib to go after Merck & Co's Keytruda, the world's top-selling medicine. 3SBio's drug works in the same way as a therapy from China's Akeso, which outperformed Keytruda in one trial. US-based Summit Therapeutics licensed Akeso's assets for US$500 million upfront in late 2022. Excitement These billion-dollar deals got bankers and investors excited. The Hang Seng Biotech Index is up about 60 per cent this year. By comparison, the S&P biotech index is down 6.5 per cent. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up There are good reasons to believe this rapid pace of dealmaking and enthusiasm for China biotech will last, with US President Donald Trump's economic policies serving as a major catalyst. Trump's threats to slash US prescription drug costs by '59 per cent, PLUS', as well as Medicaid and Medicare cuts in his big, beautiful tax and spending bill, will inevitably dent Big Pharma's bottom line. To cut in-house R&D expenses, these multinationals might have to come to China, where early-stage human tests are much cheaper and easier to run, despite comparable safety protocols. So far, the biotech industry is relatively insulated from Trump's tariffs, providing a meaningful safe haven for global investors. Rare earths materials and Boeing plane deliveries might be used as negotiation tools, but Beijing is making an exception for public health. It continues to welcome American-made medical supplies, including Pfizer's lung cancer drug Lorbrena and Merck's Gardasil, a HPV vaccine that protects against cervical cancer. Being in Beijing's good books allows Big Pharma to seal licensing deals with local partners. In addition, global drug companies and venture capital funds might want to take equity stakes too, just like Pfizer did last month. With a dip in biotech funding, especially in China, startups are unable to advance drugs on their own, and therefore demand large upfront licensing payments. This gives Western companies leverage to negotiate good deals. What is innovation without human talent? China's 'engineer dividend' is likely to pay off big time in the next few years, propelled by a hostile White House that vows to 'aggressively revoke' visas of Chinese studying in 'critical fields'. Already, the number of Chinese students in the US has dropped 22 per cent from its pre-pandemic peak, with many pointing to anti-Asian sentiment during Covid as a major drawback. Going forward, more could be forgoing US university degrees and working for promising startups at home instead. Between 2000 and 2020, the number of engineers in China ballooned from 5.2 million to 17.7 million, according to the State Council. The discipline and medicine are among the most popular fields for graduate studies. Those under the age of 30 account for 44 per cent of the total engineering pool, versus 20 per cent in the US, according to data compiled by Kaiyuan Securities. As a result, compensation for researchers is only about one-eighth that in the US. In other words, Chinese engineers are young, cheap and abundant. Tailwinds So what we've got are a lot of tailwinds: A group of strategic buyers eager to cut expenses and outsource research, a relatively benign local authority, and competitive talents. China's biotech industry is starting to dazzle. BLOOMBERG
Straits Times
2 days ago
- Straits Times
Small island states should lead, not just participate in ocean-related scientific research: Vivian
Tropical marine habitats such as coral reefs are also well-studied by scientists from other parts of the world. PHOTO: AFP NICE, France – Small island developing states have been the subjects of ocean research for too long, and should start to lead – not just participate in scientific research that would help them better understand the marine environments they depend on. Though they are the custodian s of 30 per cent of the ocean under national jurisdictions , s mall island states lead just 0.3 per cent of UN-endorsed decade of action projects on ocean health , said Singapore's Minister for Foreign Affairs, Dr Vivian Balakrishnan on June 9. Ocean decade actions are science-based programmes, projects or activities endorsed by the UN to improve ocean health. 'Small island developing states have been the subjects of ocean research for too long, the observation points in data sets, the case studies in reports and the vulnerable communities in impact assessments,' Dr Balakrishnan said at the first day of the UN Ocean Conference in Nice, France. 'Small island states are rarely the lead researchers, rarely the owners of our own ocean data. We believe that it is time to change that narrative,' he added. A large part of the summit, which ends on June 13, is focusing on boosting support for the conservation and sustainable use of oceans, seas and marine resources. Representatives from 193 countries are expected to attend. Dr Balakrishnan, who is leading a Singapore delegation, was speaking on behalf of the Alliance of Small Island States (Aosis) regarding the need for scientific cooperation for ocean health. Aosis is a grouping of 39 small island and low-lying coastal developing states including Singapore, Palau, the Maldives and Belize. Ocean-related scientific research tends to be dominated by Western scientific institutions and organisations, who have access to large oceanographic research vessels and instruments that can withstand the inhospitable conditions of the deep sea. Tropical marine habitats such as coral reefs are also well-studied by scientists from other parts of the world. However, the High Seas Treaty adopted in 2023 made it clear that such research would benefit from being more collaborative, calling on countries to provide 'opportunities for scientists of all states, in particular scientists from developing states, to be involved in or associated with the project'. The treaty is a historic agreement that lays the groundwork for international collaboration to protect oceanic areas outside national jurisdictions. Dr Balakrishnan said: 'Ocean science is not an academic luxury. Instead, it is an existential necessity for all of us small island states. The well-being of our communities, cultures, ecosystems, food security and livelihoods are dependent on a healthy and thriving ocean.' The ocean is also a treasure trove of information yet unknown, with unique organisms offering scientists the chance to obtain valuable scientific data that can improve life on land. A glow-in-the-dark jellyfish, for instance, inspired the development of a fluorescent dye that enabled doctors to track the movement of cancer cells. Dr Balakrishnan said that Aosis member states are calling for more capacity-building initiatives based on their needs, and the need to include traditional and indigenous knowledge into global frameworks from the outset. Aosis is also calling for a 'fundamental rebalancing of ocean science leadership', he said. 'We need dedicated funding mechanisms and institutional support to ensure small island developing states' research institutions can lead initiatives that address our specific challenges.' Singapore has a thriving marine research community, with a national facility – the St John's Island National Marine Laboratory – and a research institute focusing on marine science, the Tropical Marine Science Institute at the National University of Singapore . Researchers from these institutions, as well as the National Parks Board (NParks) and Nanyang Technological University's Asian School of the Environment and Earth Observatory of Singapore, are active in initiating and conducting a range of studies of the marine environment. These include research into marine creatures such as reef fish and giant clams, as well as in coral reefs, seagrass meadows and other marine ecosystems. Underwater robotics, maritime research, and studies looking into oceanographic parameters like waves are also conducted in Singapore. The focus on the need for a strong scientific basis in ocean policy was further underpinned by an event held ahead of the UN Ocean Conference which served as the scientific foundation of the summit. The One Ocean Science Congress, held in Nice from June 3 to 6, was attended by Dr Karenne Tun, the group director of the National Biodiversity Centre at NParks. She told The Straits Times that the congress offered NParks, Singapore's lead agency for marine conservation, the opportunity to both learn and contribute to the global scientific community. 'As a small island city-state, Singapore is surrounded by coastal and marine areas that are vital not only to our own environment, but also integral to the broader South-east Asian region,' she said. Singapore's waters are home to about 250 hard coral species and about 700 marine fish species. Studies have shown that hawksbill turtles migrate between Singapore and Malaysia. 'Our investment in multi- and transdisciplinary research, for example in the areas of taxonomy (the science of classification), environmental monitoring, habitat restoration, nature-based solutions and climate change impact science, can contribute to finding solutions beyond our shores.' Dr Tun said Singapore adopts a science-based approach to marine conservation and management, pointing to the Marine Conservation Action Plan, which sets out strategies to protect, restore, and enhance Singapore's coastal and marine habitats. NParks regularly reviews this plan to incorporate new knowledge and emerging technologies. She added: 'Through multilateral platforms such as the One Ocean Science Congress, Singapore can leverage scientific research outcomes generated by the global research community to complement local research efforts to guide the conservation and management of our blue spaces, while sharing our knowledge with others at the same time.' Audrey Tan is an assistant news editor overseeing sustainability coverage. She has reported on the environment for more than a decade and hosts the Green Pulse podcast series. Find out more about climate change and how it could affect you on the ST microsite here.
Business Times
2 days ago
- Business Times
Huawei chips are one generation behind US but firm is finding workarounds: CEO
[BEIJING] Huawei Technologies' chips are one generation behind those of US peers but the firm is finding ways to improve performance through methods such as cluster computing, Chinese state media quoted CEO Ren Zhengfei as saying on Tuesday. The chipmaker invests 180 billion yuan (S$32.3 billion) in research annually and sees promise in compound chips - or chips made from multiple elements - Ren said in an interview in the People's Daily newspaper of the governing Communist Party. The public comments are the first from Ren or Huawei about the firm's advanced chip manufacturing efforts. US export controls since 2019 have prevented Huawei from accessing high-end chips and equipment to manufacture them. Huawei has since marketed its Ascend series of artificial intelligence chips which compete in China with offerings from US rival Nvidia, the global leader in AI chips. The US Commerce Department last month said use of Ascend chips would be a violation of export controls. Huawei is just one of many Chinese chipmakers, Ren said in the interview. 'The United States has exaggerated Huawei's achievements. Huawei is not that great. We have to work hard to reach their evaluation,' he said. 'Our single chip is still behind the US by a generation. We use mathematics to supplement physics, non-Moore's law to supplement Moore's law and cluster computing to supplement single chips and the results can also achieve practical conditions,' he said. Cluster computing is when multiple computers work together. Moore's law refers to the speed of chip advancement. REUTERS
